A biotechnology startup in New York City is publicly making the case that the benefits of editing disease-causing genes in human embryos may now outweigh the risks—a position that directly challenges a legal and ethical consensus that has held for years. The company, Origin Genomics, argues that its technology could one day allow couples carrying devastating genetic mutations to have healthy biological children, and it is inviting a reexamination of the rules that currently make such work a crime in many jurisdictions.
The firm's founder and CEO, Cathy Tie, recently gave NPR an exclusive tour of the company's laboratory facilities, though she asked that the exact location be withheld for security reasons. The invitation offered a rare glimpse into a field that has largely operated underground or overseas because of widespread legal prohibitions and intense ethical scrutiny.
During the visit, Tie put on a white lab coat embroidered with her name and the Origin Genomics logo before leading a reporter, photographer, and videographer into the lab. Once inside, she donned blue rubber gloves and pointed out a gray metal tank resembling an oversized thermos—a cryogenic storage unit filled with liquid nitrogen.
"That is where our embryos are stored," Tie explained, twisting open the black lid and releasing wisps of white vapor into the air. She then pulled out a long metal rod holding frosted glass tubes at its tip. Four tubes were visible, and according to Tie, each one can hold as many as ten embryos. The stored embryos carry disease-causing mutations and were donated by couples whose families have been afflicted for generations by serious genetic disorders.
The company's approach involves deriving stem cells from these donated embryos to test its gene-repair technology. The goal is to demonstrate that editing genes responsible for inherited diseases can be done safely and effectively before any consideration of clinical use. Origin Genomics contends that refining the technique in the lab is a necessary step toward eventually helping families who have few other options.
The ethical and legal stakes are considerable. In the United States and much of the world, implanting a genetically modified human embryo to establish a pregnancy is prohibited. The restriction dates back to widespread alarm in the scientific community, particularly after a Chinese researcher shocked the world in 2018 by creating gene-edited twins. That case drew near-universal condemnation and led to calls for a global moratorium on heritable genome editing.
Despite the ban, some scientists and bioethicists have begun questioning whether an absolute prohibition remains the right approach. They note that gene editing technology has advanced rapidly, becoming more precise and potentially safer. Some argue that a carefully regulated pathway—one that distinguishes between editing for disease prevention and editing for enhancement—could eventually be justified, especially for parents facing the certainty of passing on fatal conditions.
Critics, however, warn that loosening restrictions could open the door to designer babies, exacerbate social inequalities, and lead to unintended consequences that would be passed down through generations. They also point out that alternative options already exist, including preimplantation genetic testing, which can screen embryos for many inherited disorders without altering their DNA.
Origin Genomics appears to be positioning itself at the center of this emerging debate. By showcasing its laboratory work, the company is attempting to shift the conversation from blanket prohibition to evidence-based assessment. Tie and her team suggest that the potential for relieving human suffering is too significant to be dismissed without a thorough review of the science.
The embryos used in Origin's research came from couples who have personally experienced the toll of genetic disease. One wife and husband who donated embryos later spoke with NPR about their hope of having healthy children with the help of gene editing—a hope that current law prevents them from pursuing in the United States.
For now, the company's work remains confined to the laboratory. No edited embryos are being implanted, and no pregnancies have been attempted. But by making its case publicly, Origin Genomics is testing whether the long-standing ethical consensus can withstand a new generation of technological capability and a growing sense of urgency among affected families.
The broader scientific community remains deeply divided. Some researchers emphasize that the risks of off-target edits and mosaicism—where only some cells in an embryo carry the intended change—have not been fully resolved. Others argue that if the technology can be proven safe, prohibiting it outright denies relief to families with no other path to a healthy child.
Regulators, meanwhile, have shown little appetite for revisiting the prohibition. Any shift would require not only scientific evidence but also broad public deliberation, given the profound implications for human identity and future generations. Origin Genomics' efforts are unlikely to change the law quickly, but they may force a more nuanced conversation about where the line should be drawn and who gets to decide.
(0)